Serum Tumor Markers for Malignancies
Defines reimbursement stance and covered indications for serum tumor markers and related biomarkers used in cancer workup, monitoring, and prognosis for Blue Cross Blue Shield - Texas members.
Replaced the term "serum tumor markers" with the broader term "biomarkers" in the initial note and in item #1 to better reflect markers that are not strictly serum-based.
Multiple individual biomarker indications were added, removed, or clarified (examples include ALP, AFP, beta-2-microglobulin, BNP/NT-proBNP, calcitonin, CA15-3/27.29, CA19-9, CA-125, CEA, HE4, inhibin, serum free light chains).
Added Castleman disease as an indication for workup with Beta-2 microglobulin and serum free light chains.
Moved systemic light chain amyloidosis initial diagnostic workup from BNP/NT-proBNP section to a separate section with Troponin T.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.